Efficacy and safety of low-dose thalidomide combined with mesalazine in the treatment of refractory ulcerative colitis in adults

作     者：Jun-Rong Chen Lei Mai Jia-Chen Sun Xiang Peng Min Zhang Min Zhi 

作者机构：Department of General PracticeThe Sixth Affiliated HospitalSun Yat-sen UniversityGuangzhouGuangdongP.R.China Department of GastroenterologyThe Fifth Affiliated HospitalSun Yat-sen UniversityZhuhaiGuangdongP.R.China Department of Gastrointestinal EndoscopyThe Sixth Affiliated HospitalSun Yat-sen UniversityGuangzhouGuangdongP.R.China Department of GastroenterologyThe Sixth Affiliated HospitalSun Yat-sen UniversityGuangzhouGuangdongP.R.China 

出 版 物：《Gastroenterology Report》 (胃肠病学报道（英文）)

年 卷 期：2022年第10卷第1期

页      面：653-655页

核心收录：

学科分类：1002[医学-临床医学] 10[医学] 

基　　金：supported by the Sun Yat-sen University Clinical Research 5010 Program[grant number 2014008] the Sixth Affiliated Hospital of Sun Yat-sen University of Horizontal Program[grant number H202101162024041054]. 

主　　题：healing clinical treatment 

摘      要：Introduction Inducing and maintaining clinical remission and mucosal healing is essential in the treatment of ulcerative colitis(UC),a nonspecific chronic recurrent inflammatory disorder[1].Mesalazine(5-ASA)is commonly prescribed as a first-line drug for UC.Despite the short-term efficacy of ciclosporin and infliximab,some patients may develop methylprednisolone resistance or dependence[2].